Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19815176 | 1.00 | MDM4 (0.49) | MDM4TP53MDM2CASP3BACE1 | |
| SCHEMBL19410141 | 0.87 | MDM4 (0.47) | MDM4TP53MDM2CASP3 | |
| SCHEMBL19410142 | 0.87 | MDM4 (0.47) | MDM4TP53MDM2CASP3 | |
| SCHEMBL31407296 | 0.85 | ACE (0.48) | — | |
| SCHEMBL21315777 | 0.83 | MDM4 (0.47) | MDM4TP53MDM2CASP3 | |
| SCHEMBL21315780 | 0.83 | MDM4 (0.47) | MDM4TP53MDM2CASP3 | |
| SCHEMBL1709188 | 0.82 | ADAM17 (0.51) | MDM4TP53MDM2BACE1 | |
| SCHEMBL5969202 | 0.82 | ADAM17 (0.51) | MDM4TP53MDM2BACE1 | |
| SCHEMBL30917941 | 0.82 | ADAM17 (0.51) | MDM4TP53MDM2BACE1 | |
| SCHEMBL1000833 | 0.82 | ADAM17 (0.51) | MDM4TP53MDM2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3491005-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018020358-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018020358-A1 | CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270778-A1 | Cyclic Peptides As C5a Receptor Antagonists | C3AR1, C5AR1, C5AR2 | MDM4 4574/4885TP53 2460/4885MDM2 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.